NCT03848832 - Efficacy and Safety of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 29, 2019

Primary Completion Date

January 21, 2021

Study Completion Date

January 21, 2021

Conditions

Rett SyndromeRTT

Interventions

DRUG

GWP42003-P

GWP42003-P presented as an oral solution containing cannabidiol

DRUG

Placebo

Matching placebo oral solution

Trial Locations (26)

10467

Clinical Trial Site, The Bronx

16147

Clinical Trial Site, Genoa

19104

Clinical Trial Site, Philadelphia

20142

Clinical Trial Site, Milan

21205

Clinical Trial Site, Baltimore

28009

Clinical Trial Site, Madrid

28040

Clinical Trial Site, Madrid

29646

Clinical Trial Site, Greenwood

37232

Clinical Trial Site, Nashville

45229

Clinical Trial Site, Cincinnati

46026

Clinical Trial Site, Valencia

55101

Clinical Trial Site, Saint Paul

60612

Clinical Trial Site, Chicago

77030

Clinical Trial Site, Houston

80045

Clinical Trial Site, Aurora

92123

Clinical Trial Site, San Diego

98124

Clinical Trial Site, Messina

35294-0021

Clinical Trial Site, Birmingham

02115

Clinical Trial Site, Boston

63110-1093

Clinical Trial Site, St Louis

00165

Clinical Trial Site, Rome

08022

Clinical Trial Site, Barcelona

08950

Clinical Trial Site, Barcelona

L12 2AP

Clinical Trial Site, Liverpool

SE1 7EU

Clinical Trial Site, London

SE5 8BB

Clinical Trial Site, London